Most notably, the present study identified that the overall survival time in CLL patients whose samples were obtained prior to the administration of any therapy (n=49) was significantly different between those exhibiting low and high CD14+HLA-DRlow/− expression levels, and that CD14+HLA-DRlow/− expression was inversely correlated with survival time (P<0.0001; Fig. 2A). Here, CD14 is linked to B-cell chronic lymphocytic leukemia.